SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

March 01, 2010 16:30 ET

SciClone Pharmaceuticals to Present at Three Investor Conferences in March

Rodman & Renshaw Annual China Investment Conference on Monday, March 8 at 4:05 pm Beijing Time; Cowen Healthcare Conference on Tuesday, March 9 at 3:45 pm ET; Roth Growth Stock Conference on Tuesday, March 16 at 11 am PT

FOSTER CITY, CA--(Marketwire - March 1, 2010) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. SciClone's executives will present a corporate overview and business update at each conference.

WHEN:   Rodman & Renshaw Annual China Investment Conference
        Monday, March 8; 4:05 pm Beijing time
        Beijing, China
        Presenter: Friedhelm Blobel, Ph.D., President and CEO

WHEN:   Cowen Healthcare Conference
        Tuesday, March 9; 3:45 pm ET
        Boston, MA
        Presenter: Gary Titus, Senior Vice President and CFO

WHEN:   Roth Growth Stock Conference
        Tuesday, March 16; 11:00 am PT
        Laguna Niguel, CA
        Presenter: Gary Titus, Senior Vice President and CFO

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty pharmaceutical company with a substantial international business, based primarily in the People's Republic of China, and with a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.